Avidity Biosciences, Inc.
RNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,244,805 | $660,759 | $1,157,475 | $984,744 |
| - Cash | $219,868 | $185,082 | $340,396 | $320,448 |
| + Debt | $6,801 | $9,852 | $10,687 | $11,729 |
| Enterprise Value | $3,031,738 | $485,529 | $827,766 | $676,025 |
| Revenue | $10,897 | $9,560 | $9,224 | $9,326 |
| % Growth | 14% | 3.6% | -1.1% | – |
| Gross Profit | $10,897 | $7,459 | $7,837 | -$91,856 |
| % Margin | 100% | 78% | 85% | -984.9% |
| EBITDA | -$376,160 | -$233,497 | -$177,526 | -$117,412 |
| % Margin | -3,452% | -2,442.4% | -1,924.6% | -1,259% |
| Net Income | -$322,302 | -$212,220 | -$173,995 | -$118,009 |
| % Margin | -2,957.7% | -2,219.9% | -1,886.3% | -1,265.4% |
| EPS Diluted | -2.89 | -2.91 | -3.34 | -2.85 |
| % Growth | 0.7% | 12.9% | -17.2% | – |
| Operating Cash Flow | -$300,870 | -$119,064 | -$136,268 | -$94,813 |
| Capital Expenditures | -$7,066 | -$4,228 | -$2,823 | -$3,740 |
| Free Cash Flow | -$307,936 | -$123,292 | -$139,091 | -$98,553 |